Abstract. An increasing body of evidence suggests that cancers contain a small subset of their own stem-like cells called cancer stem cells (CSCs), which play critical roles in the initiation, maintenance and relapse of tumors. However, the role of CSCs in cancer metastasis, especially in metastasis to bone, has not been extensively studied. Side population (SP) has been shown to enrich CSCs in several types of cancer, including breast cancer. In the present study, we characterized the SP cells isolated from the human breast cancer cell line MDA-MB-231 in comparison to non-SP (NSP). Fluorescenceactivated cell sorter analysis demonstrated the existence of SP in MDA-MB-231 cells, which was markedly reduced in the presence of fumitremorgin C, a specific inhibitor of ATP-binding cassette sub-family G member 2 (ABCG2). Quantitative RT-PCR analysis showed that ABCG2 mRNA expression was significantly higher in SP cells than in NSP cells. SP cells formed increased numbers of tumor-spheres in suspension culture. Furthermore, the tumor growth in the orthotopic mammary fat pad in nude mice was significantly accelerated in SP cells. On the other hand, the development of bone metastases determined by intracardiac injection into nude mice showed no difference between SP and NSP cells. SP abundance in the tumor cells isolated from the bone metastases was not increased either compared with that from the mammary tumors. These results suggest that the SP in MDA-MB-231 cells possesses some of the CSC-like properties but does not have higher metastatic potential to bone.
Introduction
Despite the monoclonal origins, cancers are composed of a heterogeneous population of cells with different properties. It has recently been suggested that, within a given tumor, there exists a small population of cells with the capacity to behave like stem cells called cancer stem cells (CSCs) (1) . This concept, which was first established in hematological malignancies (2) , has been adapted for a growing number of solid tumors, including breast cancer (1, 3) . CSCs are characterized by extensive self-renewal and proliferative capacity and resistance to chemotherapy and radiotherapy (1) . These characteristic features play pivotal roles in the initiation, maintenance and relapse of tumors. Thus, CSCs are emerging as an important target for cancer therapy.
For identification and isolation of CSCs, several approaches have been proposed. In breast cancers, cell surface markers, such as CD24 and CD44, have been proved to be useful for the isolation of subsets enriched for breast CSCs (1, 3) . High aldehyde dehydrogenase (ALDH) activity was also recently shown to identify the CSC fraction in breast cancer cells (4) . An alternative approach is the side population (SP) phenomenon (5) . Owing to the ability to exclude the DNA binding dye Hoechst 33342, SP cells are identified as a tail of dimly stained cells in dual wavelength fluorescent-activated cell sorter (FACS) analysis. Since the original discovery that SP cells in mouse bone marrow are highly enriched for longterm repopulating cells (6) , SP cells have been identified in a variety of normal tissues and cancers, including breast cancer and shown to have stem cell-like properties (5, 7) .
Bone is one of the most preferential metastatic target sites for breast cancer (8) . It has been recently suggested that CSCs play an important role in mediating the metastasis of breast cancer (9, 10) . However, it has yet to be elucidated whether CSCs contribute to the development of bone metastases.
In this study, we identified SP in the human breast cancer cell line MDA-MB-231 and characterized the SP cells as potential CSC-like cells. By taking advantage of the bone metastatic potential of MDA-MB-231 cells in a nude mouse model (11) , we examined the ability of SP cells to metastasize to bone. 
FACS analysis and cell sorting. SP analysis and sorting:
The protocol was based on Goodell et al (6) with slight modifications. Briefly, MDA-MB-231 cells (1x10 6 cells/ml) were incubated in Hanks' Balanced Salt Solutions (HBSS) supplemented with 2% FBS, 10 mM HEPES, 1% penicillin/ streptomycin and 5 μg/ml Hoechst 33342 for 60 min at 37˚C with intermittent mixing. In some experiments, cells were incubated with the Hoechst dye in the presence of 2 μM FTC or 50 μM verapamil. After incubation, cells were washed with cold medium and resuspended at 2x10 6 cells/ml, and propidium iodide was added to a final concentration of 2 μg/ml to discriminate dead cells. The gating of SP was based on negative controls in which FTC was used.
SP analysis of tumors from mice: MDA-MB-231 cells were inoculated into the mammary fat pad (5 million cells/ 0.1 ml PBS) or the left cardiac ventricle (0.1 million cells/ 0.1 ml PBS) of athymic nude mice (female, 4-week-old, Japan SLC, Inc., Shizuoka, Japan) under anesthesia with pentobarbital (0.05 mg/g body weight; Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan) (11) . Four weeks after the inoculation, mammary tumors and bone metastases were dissected, minced with scalpels and strained through stainless steel mesh. The cells suspended with the culture medium were plated in 10 cm dishes and cultured overnight to remove dead cells and cell debris. Then, SP analysis was performed as described above.
CD24 and CD44 immunostaining: MDA-MB-231 cells were stained with rat monoclonal antibodies against CD24 (FITC-conjugated) and CD44 (PE-conjugated) or isotypematched IgG controls (all from eBiosciences, Inc., San Diego, CA).
Aldehyde dehydrogenase (ALDH) activity: ALDH enzymatic activity of MDA-MB-231 cells was examined using AldeFluor Kit (StemCell Technologies, Durham, NC) according to the manufacturer's protocol.
All FACS analysis and cell sorting were performed using a BD FACSVantage SE cell sorter (Becton-Dickinson and Co.). The data were analyzed by BD CellQuest Pro software (Becton-Dickinson and Co.).
Cell proliferation in monolayer. SP and NSP of MDA-MB-231 cells (1,000 cells/well/96-well plate) were plated in DMEM supplemented with 10% FBS and 100 μg/ml kanamycin sulfate and cultured for 24, 72 and 96 h. At the end of the culture, the cell proliferation was determined using Cell Proliferation Reagent WST-1 (Roche Diagnostics K.K., Tokyo, Japan) according to the manufacturer's protocol. The absorbance was measured using a microplate reader (Nippon Bio-Rad Laboratories, Tokyo, Japan) at a wavelength of 450 nm.
Tumor-sphere formation. Tumor-sphere formation assay was performed as described previously with some modifications (12) . SP and NSP isolated from MDA-MB-231 cells were plated in ultra-low attachment 6-well plates (Corning Japan K.K., Tokyo, Japan) at a density of 2,000 cells/well and cultured in DMEM/F12 (Sigma-Aldrich) containing 2% B27 supplement, 40 ng/ml rhFGF-2 and 20 ng/ml rhEGF for 10 days. The cells were replenished with fresh proliferation medium every 3 days. At the end of the culture, the number of tumorspheres of >100 μm in diameter was counted under a microscope and expressed as the number of tumor-spheres/ well.
Quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR).
Total RNA was isolated using RNeasy Plus Micro Kit (Qiagen K.K., Tokyo, Japan). Reverse transcription and real-time PCR was performed using One
Step SYBR PrimeScript Plus RT-PCR Kit (Takara Bio Inc., Shiga, Japan) in DNA Engine Opticon system (Bio-Rad Laboratories, K.K., Tokyo, Japan) according to the manufacturer's protocol. Primer sequences were as follows: ATPbinding cassette transporters sub-family G member 2 (ABCG2), TGGCTTAGACTCAAGCACAGC/TCGTCC CTGCTTAGACATCC; ABCB1, ACAGAAAGCGAAGCA GTGGT/ATGGTGGTCCGACCTTTTC; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), AGCCACATCGCTC AGACAC/GCCCAATACGACCAAATCC. Melting curve analysis was performed to determine the melting temperature of the amplified product and to exclude undesired primer dimers. Each sample was run at least in triplicate. Quantification was normalized using GAPDH as a reference gene. Expression levels of the particular genes were indicated as fold increase compared with the control.
Microarray analysis. Total RNA was extracted from SP and NSP cells using RNeasy Plus Micro Kit. The RNAs were subjected to microarray full service (Biomatrix Research, Inc., Chiba, Japan) and assessed using GeneChip Human Gene 1.0 ST Array (Affymetrix, Inc., Santa Clara, CA). Array image was scanned and analyzed with GeneChip operating software (Affymetrix, Inc.). Data mining was conducted using GeneSpring software (Agilent Technologies, Inc., Santa Clara, CA).
Animal experiments. Tumorigenesis in mammary fat pad:
Under anesthesia with pentobarbital, SP and NSP cells (1,000 or 3,000 cells/0.1 ml matrigel) were injected into the mammary fat pad of athymic nude mice (female, 4-week-old, Japan SLC, Inc.). The size of orthotopic tumors was measured once a week using a caliper. The tumor volume was estimated by the following equation: tumor volume (mm 3 ) = (length) x (width) 2 x 0.5. Bone metastasis: SP and NSP cells (10,000 cells/0.1 ml PBS) were injected into the left cardiac ventricle of athymic nude mice (female, 4-week-old, Japan SLC, Inc.) under anesthesia with pentobarbital as described previously (11) .
The number of mice used in each experiment is described in each figure. All animal experiments were reviewed and approved by the Animal Management Committee of Matsumoto Dental University.
X-ray analysis. Number and area of osteolytic lesions in the femora and tibiae were determined on radiographs as described previously (11) . Data are shown as number of metastases/ mouse or lesion area (mm 2 )/mouse.
Statistical analysis. Data are expressed as the mean ± SEM. The data were analyzed by one-way ANOVA followed by Fisher's PLSD post-hoc test (StatView; SAS Institute, Inc., Cary, NC) for determination of differences between groups. Student's t-test or Welch's t-test was conducted when two groups were compared. P-values of <0.05 were considered significant.
Results

Expression of CSC markers in MDA-MB-231 human breast cancer cells. FACS analysis demonstrated that MDA-MB-231
cells after Hoechst 33342 staining were clearly separated into a fluorescence-negative tail of SP (3.40±0.60%, average of 10 independent experiments) and the brightly stained NSP (Fig. 1A) . We also examined other potential CSC markers, CD24/CD44 expression and ALDH activity, in MDA-MB-231 cells. Most of the cells were CD24 -/CD44 + ( Fig. 1D) and only a small number of the cells showed ALDH activity (Fig. 1E) . Therefore, in the following experiments, we studied the SP of MDA-MB-231 cells as potential CSC-like cells in comparison to the NSP cells.
Characterization of SP cells in vitro.
To examine the repopulation ability of the SP of MDA-MB-231 cells, SP and NSP cells were cultured for 2 weeks after cell sorting. Then, the cells were restained with Hoechst 33342 and reanalyzed by FACS. SP cells generated both SP and NSP with fraction size larger than or comparable to the original population (Fig. 2) . The SP fraction generated from NSP was smaller than that from SP (Fig. 2) .
ABC transporters, especially ABCG2, also known as breast cancer resistance protein (BCRP), and ABCB1, also known as multidrug resistance protein 1 (MDR1), have been implicated as being responsible for the SP phenotype (13, 14) . Consistent with this notion, quantitative RT-PCR analysis showed that ABCG2 mRNA expression was significantly higher in SP cells than in NSP cells (Fig. 3A) , while ABCB1 mRNA was undetectable in both types. Furthermore, the SP fraction was markedly decreased in the presence of FTC, a specific inhibitor of ABCG2 (15), but not in the presence of verapamil, an inhibitor of ABCB1 (16) (Fig. 1B, C) .
It has been reported that ABC transporters are involved in drug resistance in cancer cells (17) . To determine the relationship between the SP phenotype and drug resistance, we tested the expression of ABC transporters and the SP abundance using MDA-MB-231 cells resistant to doxorubicin and 5-FU, the chemotherapeutic agents widely used for the treatment of breast cancer. ABCG2 mRNA expression was significantly up-regulated in the doxorubicin-resistant cells in a dosedependent manner (Fig. 3B) , whereas ABCB1 mRNA was not detected in any of the drug-resistant cells. Furthermore, the SP abundance was increased in the doxorubicin-resistant cells (Fig. 3C) . These changes were not observed in the 5-FUresistant cells (data not shown).
We then examined the cell proliferation of SP in vitro. Monolayer cell proliferation of SP cells was similar to that of NSP cells (Fig. 4A) . In contrast, the tumorsphere formation in suspension culture was significantly enhanced in SP cells (Fig. 4B ).
Tumorigenic and metastatic potential of SP cells in nude mice.
To examine the tumorigenicity in vivo, the SP of MDA-MB-231 cells were inoculated into the mammary fat pad in nude mice. Tumor formation rates at 8 weeks after the cell inoculation were similar between SP and NSP cells (Table I) . However, the tumor growth of SP cells was significantly accelerated compared with that of NSP cells (Fig. 5A) .
The bone-metastatic potential of SP cells was next examined by inoculating the cells into the left cardiac ventricle in nude mice. Radiographic analysis demonstrated that both SP and NSP cells developed osteolytic bone metastases (Fig. 5B) . The incidences of metastasis were similar between SP and NSP (NSP: 10/15, SP: 9/15, the number of mice with metastases/total mice). There was no significant difference in the lesion number and area (Fig. 5B, C) .
SP abundance in bone metastases.
We examined whether SP is increased in bone metastases by inoculating parental MDA-MB-231 cells into nude mice. The SP abundance in the tumor cells in bone metastases was comparable to that in the mammary tumors and in parental MDA-MB-231 cells in culture (Fig. 6 ).
Gene expression profile of SP cells. We finally performed a comprehensive analysis of gene expression differences between SP and NSP cells. The microarray data demonstrated that 44 genes showed more than 1.5-fold up-regulation and 29 genes showed a >1.5-fold down-regulation (Table II) . However, no up-regulation of known stem cell markers, potential cancer stem cell markers and metastasis-related genes was found in SP cells.
Discussion
Although several markers have been proposed to identify CSCs, the definitive markers have not been established in any types of CSC. In breast cancers, the cell surface markers CD24 -/low /CD44 + , high ALDH activity and SP are considered to be potential markers for CSCs (1, (3) (4) (5) 7) . However, it is curious that the cell populations isolated using these markers do not always overlap (4) . Consistent with these results, our data show that most MDA-MB-231 cells were CD24 -/CD44 + , ONCOLOGY REPORTS 25: 289-296, 2011 Table I . Tumorigenicity of the SP of MDA-MB-231 cells in nude mice.
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Furthermore, the NSP developed tumors in mammary fat pad in nude mice at a similar rate to the SP. These results collectively suggest that the SP of MDA-MB-231 cells possesses some of the CSC-like properties but does not completely meet the criteria for CSCs.
It has been suggested that the SP phenotype is conferred by the expression of ABC transporters, especially ABCB1 and ABCG2 (13, 14) . The SP fraction of MDA-MB-231 cells was eliminated in the presence of an ABCG2-specific inhibitor FTC. ABCG2 mRNA expression was significantly upregulated in SP cells compared with that in NSP cells. These results suggest that ABCG2 is responsible, at least in part, for the SP phenotype of MDA-MB-231 cells.
CSCs are thought to be resistant to chemotherapy. One mechanism by which this may arise is through the expression of ABC transporters. In this respect, SP cells share similar properties with CSCs. The doxorubicin-resistant MDA-MB-231 cells exhibited higher ABCG2 expression and increased ONCOLOGY REPORTS 25: 289-296, 2011 295 Table II . Continued.
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Up-(>1.5-fold) and down-regulated (>1.5-fold) genes in the SP of MDA-MB-231 cells are shown. NA, not applicable.
SP fraction, suggesting a relationship between the SP phenotype and drug resistance. In contrast, these changes were not found in the 5-FU-resistant cells. Since ABC transporters responsible for the efflux of each chemotherapeutic agent are variable (17) , it may be possible that 5-FU is effluxed by ABC transporters other than ABCB1 and ABCG2 in MDA-MB-231 cells.
The development of distant metastases is the major cause of death in patients with breast cancer. However, the role of CSCs in multistage cancer progression, particularly with respect to metastasis, has not been well defined. Breast cancer cells with CD24 -/CD44 + subpopulation have been shown to have higher invasive properties (20) . ALDH-positive populations of mammary carcinoma cell lines also display increased invasive characteristics (10) . These findings suggest that CSCs possess higher metastatic potential. Furthermore, Balic et al have revealed an increase in CD24 -/CD44 + cancer cells disseminated in bone marrow in breast cancer patients (21) , suggesting that CSCs may have high metastatic potential to bone. Meanwhile, there are some reports showing that CSC phenotype alone is not enough to determine metastasis (1, 20) . Our results show that SP cells did not exhibit up-regulation of metastasis-related genes and did not cause increased metastases to bone. These results suggest that CSCs may not have higher metastatic potential to bone. Experiments using the definitive CSCs have to be performed to determine the role of CSCs in cancer metastasis.
We also found that the SP abundance in bone metastases in nude mice is comparable to those in mammary fat pad and in parental MDA-MB-231 cells in culture. However, the data do not exclude the possibility that SP cells may have a higher metastatic potential than NSP cells, because the results including ours indicate that the ratio of SP to NSP cells reached a steady state within a few weeks (22) . Thus, it is possible that cancer cells initially metastasize as SP and then change their phenotype following limited differentiation at their new site.
It has been argued that the phenotypic differences between SP and NSP cells are a consequence of damage induced by the Hoechst dye, which is retained longer in NSP cells. Christgen et al proposed that the Hoechst dye directly affects the expression of stemness-related genes (23) . In our study, monolayer cell proliferation was similar between SP and NSP. The expression of stem cell genes was also unaffected in NSP cells compared to that in SP cells. Thus, it is unlikely that the Hoechst dye directly caused the difference between SP and NSP in MDA-MB-231 cells, although it is difficult to exclude the possibility.
In conclusion, our results suggest that the SP of MDA-MB-231 cells possesses some of the properties of CSCs but does not have a higher metastatic potential to bone. However, since definite markers for CSCs have not been established yet, further studies are required to determine the bone metastatic potential of CSCs.
